Vaxcyte raises $1.42B in underwritten public offering of common stock and pre-funded warrants

Vaxcyte, Inc.

Sold 10,194,175 shares at $103.00/share and pre-funded warrants to purchase 2,427,184 shares at $102.999/warrant.
Underwriters' 30-day option for additional 1,893,203 shares exercised in full.
Net proceeds expected to be approximately $1.42 billion after discounts and expenses.
Closing expected on or about September 6, 2024, subject to customary conditions.
Offering made under effective shelf registration statement (Form S-3).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.